Probiotics modulate the gut microbiota composition and immune responses in patients with atopic dermatitis: a pilot study

2019 ◽  
Vol 59 (5) ◽  
pp. 2119-2130 ◽  
Author(s):  
Zhifeng Fang ◽  
Wenwei Lu ◽  
Jianxian Zhao ◽  
Hao Zhang ◽  
Long Qian ◽  
...  
2020 ◽  
Vol 158 (6) ◽  
pp. S-547-S-548
Author(s):  
Sila Cocciolillo ◽  
Giada De Palma ◽  
Tianyan Chen ◽  
Maged Peter Ghali ◽  
marc deschenes ◽  
...  

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S650-S651
Author(s):  
S Cocciolillo ◽  
G De Palma ◽  
T Chen ◽  
M P Ghali ◽  
M Deschenes ◽  
...  

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is the main cause of liver disease in Western countries and is a frequently reported comorbidity in inflammatory bowel disease (IBD). A complex interaction among polygenic predisposition, IBD-specific risk factors, microbiome, multiple environmental and patients’ factors could explain the development of NAFLD in IBD. Gut dysbiosis is increasingly recognised as an important player in NAFLD, as well as in IBD pathogenesis. So far, no study has examined the gut microbiota composition in IBD patients with NAFLD. We aimed to characterise faecal microbiota according to NAFLD status in a pilot cohort of ulcerative colitis (UC) pancolitis in clinical remission. Methods This was a cross-sectional pilot study using transient elastography (TE) with controlled attenuation parameter (CAP) to diagnose NAFLD in UC pancolitis patients in clinical remission, defined as partial Mayo score ≤1. NAFLD was diagnosed non-invasively as CAP ≥248 dB/m. Exclusion criteria included: use of corticosteroids in the last year and antibiotics or probiotics/prebiotics in the last 2 months prior to inclusion; significant alcohol intake (AUDIT-C <5); hepatitis B or C infection. Stool samples were collected within 12 h from TE with CAP evaluation. Gut microbiota composition was analysed by 16S rRNA gene sequencing with Illumina technique. Statistical analysis by NAFLD status was performed using Fisher’s exact or Mann–Whitney’s test as appropriate. Results A total of 11 UC pancolitis patients in clinical remission were included (mean age 53 years, 36.4% male, time since IBD diagnosis 16 years). NAFLD was diagnosed in 7 cases (63.6%, mean CAP 291 dB/m). Patients with pancolitis and NAFLD had higher BMI (mean 31 vs. 22 kg/m2, p = 0.006) as well as waist circumference (mean 100 vs. 81 cm, p = 0.006) compared with those without NAFLD, but no other differences in demographic, clinical or pharmacological parameters were found between pancolitis with or without NAFLD. Patients with pancolitis and NAFLD clustered separately from those without NAFLD, when computing Bray Curtis dissimilarities (tested with Adonis, p = 0.006). In addition, patients with pancolitis and NAFLD presented with decreased bacterial richness (p = 0.017) but not diversity. This was accompanied by a significant increase of Bacteroides spp. relative abundance in faecal samples of patients with pancolitis and NAFLD (q = 0.017). Conclusion This pilot study demonstrates, for the first time, that, in UC pancolitis patients, NAFLD associates with altered gut microbiota composition. Further studies are needed to understand the exact role of gut microbiota in UC pancolitis with NAFLD and to evaluate the use of microbiota-directed approaches for the treatment of NAFLD in these patients.


2019 ◽  
Vol 125 ◽  
pp. 272-278 ◽  
Author(s):  
Sara Meazzi ◽  
Angelica Stranieri ◽  
Stefania Lauzi ◽  
Federico Bonsembiante ◽  
Silvia Ferro ◽  
...  

2020 ◽  
Vol 76 ◽  
pp. 140-147
Author(s):  
Francesco Valentini ◽  
Melania Evangelisti ◽  
Marta Arpinelli ◽  
Giovanni Di Nardo ◽  
Marina Borro ◽  
...  

Gut ◽  
2021 ◽  
pp. gutjnl-2020-323020 ◽  
Author(s):  
Yun Kit Yeoh ◽  
Tao Zuo ◽  
Grace Chung-Yan Lui ◽  
Fen Zhang ◽  
Qin Liu ◽  
...  

ObjectiveAlthough COVID-19 is primarily a respiratory illness, there is mounting evidence suggesting that the GI tract is involved in this disease. We investigated whether the gut microbiome is linked to disease severity in patients with COVID-19, and whether perturbations in microbiome composition, if any, resolve with clearance of the SARS-CoV-2 virus.MethodsIn this two-hospital cohort study, we obtained blood, stool and patient records from 100 patients with laboratory-confirmed SARS-CoV-2 infection. Serial stool samples were collected from 27 of the 100 patients up to 30 days after clearance of SARS-CoV-2. Gut microbiome compositions were characterised by shotgun sequencing total DNA extracted from stools. Concentrations of inflammatory cytokines and blood markers were measured from plasma.ResultsGut microbiome composition was significantly altered in patients with COVID-19 compared with non-COVID-19 individuals irrespective of whether patients had received medication (p<0.01). Several gut commensals with known immunomodulatory potential such as Faecalibacterium prausnitzii, Eubacterium rectale and bifidobacteria were underrepresented in patients and remained low in samples collected up to 30 days after disease resolution. Moreover, this perturbed composition exhibited stratification with disease severity concordant with elevated concentrations of inflammatory cytokines and blood markers such as C reactive protein, lactate dehydrogenase, aspartate aminotransferase and gamma-glutamyl transferase.ConclusionAssociations between gut microbiota composition, levels of cytokines and inflammatory markers in patients with COVID-19 suggest that the gut microbiome is involved in the magnitude of COVID-19 severity possibly via modulating host immune responses. Furthermore, the gut microbiota dysbiosis after disease resolution could contribute to persistent symptoms, highlighting a need to understand how gut microorganisms are involved in inflammation and COVID-19.


2016 ◽  
Vol 363 ◽  
pp. 153-157 ◽  
Author(s):  
Helen Tremlett ◽  
Douglas W. Fadrosh ◽  
Ali A. Faruqi ◽  
Janace Hart ◽  
Shelly Roalstad ◽  
...  

PLoS ONE ◽  
2017 ◽  
Vol 12 (10) ◽  
pp. e0186546 ◽  
Author(s):  
Andrew R. Williams ◽  
Lukasz Krych ◽  
Hajar Fauzan Ahmad ◽  
Peter Nejsum ◽  
Kerstin Skovgaard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document